GROβ在结直肠癌肿瘤血清中的表达与临床病理相关性研究  

Correlation between serum GROβ expression and clinicopathological characteristics of colorectal cancer

作　　者：郑敏[1,2] 孙思进 高红军[4] 郑朝旭[3] 岳志刚[4] 周艳秋[4] 胡万宁[1,2] 

机构地区：[1]河北联合大学附属唐山市人民医院 [2]唐山市肿瘤医院,河北省唐山市063001 [3]中国医学科学院北京协和医学院肿瘤医院 [4]煤炭总医院

出　　处：《中国肿瘤临床》2015年第10期519-524,共6页Chinese Journal of Clinical Oncology

摘　　要：目的:探讨生长相关癌基因产物β(growth-related gene productβ,GROβ)用于结直肠癌诊断潜在的可能性。方法:收集123例结直肠癌、88例健康对照及125例非肿瘤患者外周血清,ELISA法分析GROβ的含量;免疫发光法分析CEA及CA19-9的含量。统计分析不同临床特征结直肠癌之间GROβ的差异;ROC曲线评估GROβ、CEA和CA19-9诊断结直肠癌的敏感度和特异度。结果:结直肠癌血清GROβ浓度(中位数96.15 pg/m L)明显高于健康对照组(中位数43.28 pg/m L,P<0.01)和非肿瘤患者(中位数57.30 pg/m L,P<0.01)。GROβ水平与肿瘤TNM分期(P<0.01)及浸润深度均呈正相关(P<0.05),与肿瘤分化程度、肿瘤栓塞、淋巴结转移、肿瘤病理类型及性别无关。GROβ检测结直肠癌的敏感度和特异度分别为56.1%(69/123)和95.31%(203/213)。将GROβ、CEA和CA19-9阳性样本叠加后,诊断Ⅰ期结直肠癌的敏感度为22.2%(4/18),诊断Ⅱ期结直肠癌的敏感度为66.7%(26/39)。GROβ的ROC曲线下面积(0.834)高于CEA(0.739)和CA19-9(0.676)。结论:血清GROβ浓度可能是一个有效的结直肠癌检测指标。Objective：To confirm the potential of growth-related gene productβ（GROβ） as a biomarker for colorectal cancer. Methods：Serum GROβlevels in 123 subjects with colorectal cancer, 88 healthy controls, and 125 subjects with other diseases were measured using enzyme-linked immunosorbent assay. Serum levels of carcinoembryonic antigen （CEA） and carbohydrate antigen 19-9 （CA19-9） in all subjects were measured using immunoluminometric assay. Statistical analyses were conducted to determine the associa-tions between serum GROβlevels and clinical parameters for colorectal cancer. The receiver operating characteristic （ROC） curves of GROβ, CEA, and CA19-9 were analyzed. Results：The serum GROβlevels were higher in patients with colorectal cancer （median=96.15 pg/mL） than in the healthy controls （median=43.28 pg/mL, P〈0.01） and in patients with other diseases （median=57.30 pg/mL, P〈0.01）. The serum GROβlevels in patients with colorectal cancer were positively correlated with the tumor-node-metastasis staging （P〈0.01） and depth of infiltration （P〈0.05）, but not with the histological grade, tumor embolus, lymph node metastasis, gross pathologic tu-mor type, or gender of the patients. The sensitivity and specificity of the assay for serum GROβwere 56.1%（69/123） and 95.31%（203/213）, respectively. The diagnostic sensitivity was 22.2%（4/18） for stage I and 66.7%（26/39） for stage II when the data of GROβwere combined with the data of CEA and CA19-9. The ROC curve constructed with the data of GROβ（0.834） was larger than that construct-ed with the data of CEA （0.739） or CA19-9 （0.676） for discriminating colorectal cancer from the matched controls. Conclusion：These preliminary results indicated that the serum GROβlevel could be a useful biomarker for colorectal cancer diagnoses.

关 键 词：GROβ 结直肠癌 生物标志物 CEA CA19-9 

分 类 号：R735.34[医药卫生—肿瘤]